Get the Stockscreener App
142.69
1.39%
1.96
After Hours:
142.69
Glaukos Corporation stock is traded at $142.69, with a volume of 333.69K.
It is up +1.39% in the last 24 hours and up +9.27% over the past month.
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
See More
Previous Close:
$140.73
Open:
$141.75
24h Volume:
333.69K
Relative Volume:
0.66
Market Cap:
$7.82B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-53.04
EPS:
-2.69
Net Cash Flow:
$-81.27M
1W Performance:
+0.88%
1M Performance:
+9.27%
6M Performance:
+31.04%
1Y Performance:
+139.69%
1-Day Range:
$141.56
$144.51
1-Week Range:
$139.54
$146.86
52-Week Range:
$59.58
$146.86
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
142.69 | 7.82B | 360.35M | -149.57M | -81.27M | -2.69 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Ophthalmic Devices Market Worth 66.71 Bn by 2027 | Hoya Group, Gulden Ophthalmics, FCI Ophthalmics, Glaukos - EIN News
Analyst Scoreboard: 5 Ratings For Glaukos - Inkl
Glaukos price target raised to $149 from $140 at BTIG - TipRanks
Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally? - MSN
Loomis Sayles & Co. L P Grows Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
Intech Investment Management LLC Purchases 9,088 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Eagle Asset Management Inc. Has $11.12 Million Stake in Glaukos Co. (NYSE:GKOS) - MarketBeat
6,080 Shares in Glaukos Co. (NYSE:GKOS) Bought by Jennison Associates LLC - MarketBeat
Glaukos (NYSE:GKOS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Glaukos stock soars to all-time high of $145.97 amid robust growth - Investing.com Australia
When (GKOS) Moves Investors should Listen - Stock Traders Daily
Connor Clark & Lunn Investment Management Ltd. Has $6.11 Million Holdings in Glaukos Co. (NYSE:GKOS) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Buys New Shares in Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos stock soars to all-time high of $145.97 amid robust growth By Investing.com - Investing.com South Africa
Primecap Management Co. CA Increases Stock Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
Segall Bryant & Hamill LLC Sells 4,327 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Glaukos Co. (NYSE:GKOS) is Brown Capital Management LLC's 4th Largest Position - MarketBeat
Glaukos (FRA:6GJ) Cyclically Adjusted FCF per Share : €-0.43 (As of Sep. 2024) - GuruFocus.com
Glaukos Co. (NYSE:GKOS) Shares Bought by Victory Capital Management Inc. - MarketBeat
Glaukos Corp (GKOS) Trading 4.94% Higher on Nov 19 - GuruFocus.com
First Turn Management LLC Takes Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
LMR Partners LLP Grows Holdings in Glaukos Co. (NYSE:GKOS) - MarketBeat
Oppenheimer Asset Management Inc. Sells 3,974 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Here's Why You Should Retain Glaukos (GKOS) Stock for Now - MSN
Glaukos Revolutionizes Glaucoma Treatment with iDose TR Approval - TipRanks
Brown Capital Management LLC's Strategic Reduction in Glaukos Co - GuruFocus.com
(GKOS) Long Term Investment Analysis - Stock Traders Daily
Glaukos Co. (NYSE:GKOS) Shares Bought by WCM Investment Management LLC - MarketBeat
Principal Financial Group Inc. Sells 9,441 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
Lisanti Capital Growth LLC Sells 20,320 Shares of Glaukos Co. (NYSE:GKOS) - MarketBeat
GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates - MSN
Glaukos Announces Participation in Upcoming Investor Conferences - BioSpace
William Blair Comments on Glaukos' Q4 Earnings (NYSE:GKOS) - MarketBeat
Glaukos to Present at 5 Major Healthcare Investor Conferences in Q4 2024 | GKOS Stock News - StockTitan
Glaukos Corporation (NYSE:GKOS) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Glaukos stock soars to all-time high of $139.53 amid robust growth - Investing.com
Glaukos Corporation (NYSE:GKOS) Q3 2024 Earnings Call Transcript - MSN
Glaukos price target raised to $145 from $135 at Wells Fargo - Yahoo Finance
Glaukos Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Glaukos price target raised to $140 from $139 at BTIG - TipRanks
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market | Futu - WICZ
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - MSN
Glaukos (NYSE:GKOS) Shares Gap DownHere's What Happened - MarketBeat
Glaukos (NYSE:GKOS) Releases Earnings Results, Beats Estimates By $0.20 EPS - MarketBeat
Earnings call: Glaukos reports strong Q3 growth, raises 2024 guidance - Investing.com
Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
JPMorgan Chase & Co. Issues Positive Forecast for Glaukos (NYSE:GKOS) Stock Price - MarketBeat
Piper Sandler reaffirms stock target on Glaukos post-Q3 beat - Investing.com
BTIG reiterates Buy on Glaukos stock as strong iDose sales support growth outlook - Investing.com
Glaukos Co. (NYSE:GKOS) Receives $130.45 Average PT from Analysts - MarketBeat
Glaukos Corp (GKOS) Q3 2024 Earnings Call Highlights: Record Sal - GuruFocus.com
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):